RADX — Radiopharm Theranostics Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1949257 ·
Australia
Last close
$1.65
Market Cap
$23.86M
52W High
$16.25
52W Low
$1.44
ADV30
65,143
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | — | — | — | — | 92,452,231 | 36,436,938 | 40,448,518 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-127,785,301
Inventory
—
Receivables
$6,250,693
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,502,270
EBITDA
$-49,613,928
Free Cash Flow
$-30,744,724
Enterprise Value
$16,890,226
Total Cash
$4,138,074
Total Debt
$0
Shares Out
14,458,498
Trailing EPS
$-3.88
Book Value
$1.51
ROE
-174.7%
ROA
-44.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 3,633,422 | -34,640,735 | -38,342,457 | 86,481,876 | 43,609,972 | 44,792,004 | — |
| Jun 2024 | 299,228 | -37,173,885 | -47,949,119 | 72,036,345 | 44,683,059 | 28,122,562 | — |
| Jun 2023 | 292,359 | -31,690,601 | -34,611,194 | 74,949,668 | 29,370,243 | 44,384,488 | — |
| Jun 2022 | 8,831 | -19,916,352 | -30,338,979 | 83,381,291 | 20,418,572 | 62,962,719 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| UPC | Universe Pharmaceuticals INC | $23.79M | $4.75 | — |
| TXMD | TherapeuticsMD, Inc. | $23.73M | $2.05 | — |
| NXTC | NextCure, Inc. | $23.25M | $5.08 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $23.12M | $0.05 | — |
| QNTM | Quantum Biopharma Ltd. | $24.75M | $3.85 | — |
News headlines (Yahoo Finance, 1h cache)
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
2026-09-09 11:00 · Yahoo
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
2026-08-26 11:00 · Yahoo
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
2026-08-20 11:00 · Yahoo
Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases
2026-08-17 11:30 · Yahoo
RADX: RAD101 Topline & FY:26 Cash Flows
2026-08-03 15:14 · Yahoo
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
2026-09-14 12:00 · Yahoo
Radiopharm Theranostics Reports Business Update
2026-07-31 11:00 · Yahoo
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
2026-07-24 11:15 · Yahoo
Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
2026-07-22 11:05 · Yahoo
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
2026-07-22 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.